Impact of Baseline HbA1c, BMI, and Diabetes Duration on the Efficacy and Safety of LixiLan (Insulin Glargine/Lixisenatide Titratable Fixed-Ratio Combination) vs. Insulin Glargine and Lixisenatide in the LixiLan-O Trial

被引：0
|
作者：
Davies, Melanie
Leiter, Lawrence A.
Grunberger, George
Ampudia-Blasco, F. Javier
Guerci, Bruno
Yu, Christine
Stager, William
Niemoeller, Elisabeth
Souhami, Elisabeth
Rosenstock, Julio
机构：
来源：
DIABETES | 2016年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1028-P
引用
收藏
页码：A268 / A268
页数：1
相关论文
共 50 条
  • [1] Outcomes of LixiLan, a fixed-ratio combination of insulin glargine/lixisenatide, versus insulin glargine and lixisenatide by baseline characteristics: LixiLan-O trial
    Guerci, B.
    Davies, M.
    Leiter, L. A.
    Grunberger, G.
    Ampudia-Blasco, F.
    Yu, C.
    Stager, W.
    Niemoeller, E.
    Souhami, E.
    Rosenstock, J.
    [J]. DIABETOLOGIA, 2016, 59 : S384 - S384
  • [2] Consistent Outcomes across Dose Ranges with Titratable LixiLan, Insulin Glargine/Lixisenatide Fixed-Ratio Combination, in the LixiLan-O Trial
    Henry, Robert R.
    Ahren, Bo
    Davies, Melanie
    Wu, Yujun
    Handelsman, Yehuda
    Souhami, Elisabeth
    Niemoeller, Elisabeth
    Rosenstock, Julio
    [J]. DIABETES, 2016, 65 : A264 - A264
  • [3] Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents
    Davies, Melanie J.
    Leiter, Lawrence A.
    Guerci, Bruno
    Grunberger, George
    Javier Ampudia-Blasco, F.
    Yu, Christine
    Stager, William
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Rosenstock, Julio
    [J]. DIABETES OBESITY & METABOLISM, 2017, 19 (12): : 1798 - 1804
  • [4] Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial
    Rosenstock, Julio
    Aronson, Ronnie
    Grunberger, George
    Hanefeld, Markolf
    Piatti, PierMarco
    Serusclat, Pierre
    Cheng, Xi
    Zhou, Tianyue
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Davies, Melanie
    [J]. DIABETES CARE, 2016, 39 (11) : 2026 - 2035
  • [5] Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial
    Wysham, Carol
    Bonadonna, Riccardo C.
    Aroda, Vanita R.
    Puig Domingo, Manuel
    Kapitza, Christoph
    Stager, William
    Yu, Christine
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Bergenstal, Richard M.
    [J]. DIABETES OBESITY & METABOLISM, 2017, 19 (10): : 1408 - 1415
  • [6] Clinical impact of LixiLan, a fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on oral agents: LixiLan-O trial
    Rosenstock, J.
    Aronson, R.
    Hanefeld, M.
    Piatti, P.
    Serusclat, P.
    Cheng, X.
    Zhou, T.
    Niemoeller, E.
    Souhami, E.
    Grunberger, G.
    Davies, M.
    [J]. DIABETOLOGIA, 2016, 59 : S384 - S385
  • [7] Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial
    Rosenstock, Julio
    Diamant, Michaela
    Aroda, Vanita R.
    Silvestre, Louise
    Souhami, Elisabeth
    Zhou, Tianyue
    Perfetti, Riccardo
    Fonseca, Vivian
    [J]. DIABETES CARE, 2016, 39 (09) : 1579 - 1586
  • [8] Clinical Impact of Titratable Fixed-Ratio Combination of Insulin Glargine/Lixisenatide vs. Each Component Alone in Type 2 Diabetes Inadequately Controlled on Oral Agents: LixiLan-O Trial
    Rosenstock, Julio
    Aronson, Ronnie
    Hanefeld, Markolf
    Piatti, Piermarco
    Serusclat, Pierre
    Cheng, Xi
    Zhou, Tianyue
    Nie-Moeller, Elisabeth
    Souhami, Elisabeth
    Grunberger, George
    Davies, Melanie
    [J]. DIABETES, 2016, 65 : A48 - A49
  • [9] Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial
    Aroda, Vanita R.
    Rosenstock, Julio
    Wysham, Carol
    Unger, Jeffrey
    Bellido, Diego
    Gonzalez-Galvez, Guillermo
    Takami, Akane
    Guo, Hailing
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Bergenstal, Richard M.
    [J]. DIABETES CARE, 2016, 39 (11) : 1972 - 1980
  • [10] Efficacy and safety of LixiLan, a fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes not adequately controlled on basal insulin: LixiLan-L trial
    Aroda, V. R.
    Rosenstock, J.
    Wysham, C.
    Unger, J.
    Bellido, D.
    Galvez, G. Gonzalez
    Takami, A.
    Guo, H.
    Niemoeller, E.
    Souhami, E.
    Bergenstal, R. M.
    [J]. DIABETOLOGIA, 2016, 59 : S2 - S3
12345